Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
University of Illinois at Chicago
Modality
mixture
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
75High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07616453CT.gov Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT07334626CT.gov Impact of Pilates Exercises on Bone Mineral Density in Breast Cancer Survivors Receiving Hormonal Therapy | — | Recruiting | — | — | — |
NCT05523609CT.gov Vitamin D and Calcium Supplementation in Breast Cancer | — | Unknown | — | — | — |
NCT05331807CT.gov Omega-3 and Vitamin D Supplementation in Breast Cancer Women | — | Completed | — | — | — |
NCT04352777CT.gov Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer | — | Completed | — | — | — |
NCT04240106CT.gov Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) | — | Completed | — | — | — |
NCT04227327CT.gov Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) | — | Terminated | — | — | — |
NCT04088110CT.gov Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer | — | Unknown | — | — | — |
NCT03079011CT.gov PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection | — | Completed | — | — | — |
NCT02760030CT.gov Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
Show 18 more trialsShow fewer
NCT02786875CT.gov Diet, Exercise and Vitamin D in Breast Cancer Recurrence | — | Unknown | — | — | — |
NCT02936999CT.gov Vitamin D Supplementation in Women With DCIS and/or LCIS | — | Terminated | — | — | — |
NCT02914158CT.gov Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women | — | Unknown | — | — | — |
NCT02186015CT.gov Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D) | — | Completed | — | — | — |
NCT02511639CT.gov Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients | — | Completed | — | — | — |
NCT01988090CT.gov High Dose Vitamin D vs Standard Dose Vitamin D Study | — | Terminated | — | — | — |
NCT01484041CT.gov Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01480869CT.gov Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients | — | Completed | — | — | — |
NCT00859651CT.gov Vitamin D in Postmenopausal Women at High Risk for Breast Cancer | — | Completed | — | — | — |
NCT01769625CT.gov Changes in Biomarkers Using Prostaglandin Inhibitors | — | Completed | — | — | — |
NCT01425476CT.gov Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors | — | Completed | — | — | — |
NCT02394496CT.gov Overcoming Endocrine Resistance in Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT01608451CT.gov Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer | — | Terminated | — | — | — |
NCT00976339CT.gov Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer | — | Completed | — | — | — |
NCT00354302CT.gov Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial | — | Completed | — | — | — |
NCT00122356CT.gov Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment | — | Completed | — | — | — |
NCT00172068CT.gov Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow | — | Terminated | — | — | — |
NCT00200174CT.gov Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vitamin D (this asset) | University of Illinois at Chicago | Approved | BB · 69 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Vitamin D
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Vitamin D Deficiency | — | P4 | A · 83 |
| Osteoporosis | — | P4 | BBB · 76 |
| Polycystic Ovary Syndrome | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vitamin D in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vitamin-d-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →